期刊文献+

ROC曲线分析Tumor M2-PK肿瘤标志物对非小细胞肺癌的诊断价值

下载PDF
导出
摘要 目的探讨应用受试者工作特征曲线(ROC曲线)分析肿瘤标志物Tumor m^2-PK在非小细胞肺癌(NSCLC)中的诊断价值。方法应用酶联免疫吸附法分别检测66例NSCLC患者和51例肺部良性疾病患者外周血Tumor m^2-PK水平,比较两者患者中Tumor m^2-PK有无差别,同时应用ROC曲线评价Tumor m^2-PK诊断NSCLC的能力。结果 NSCLC和良性病变组中Tumor m^2-PK中位数分别为19.4 U/m L和5.8 U/m L,均为非正态分布。对Tumor m^2-PK值去对数[log(Tumor m^2-PK)],对数转换后数据为正态分布,NSCLC组log(Tumor m^2-PK)均数为(1.24±0.67),良性病变组为(0.73±0.42),NSCLC组明显高于良性病变组(P〈0.000 1);以log(Tumor m^2-PK)为指标绘制ROC曲线图,曲线下面积(AUC)为0.72(95%CI:0.62-0.81)。结论 NSCLC患者外周血Tumor m^2-PK显著高于良性病变组,Tumor m^2-PK鉴别NSCLC的诊断效能尚可。
作者 韩晓莉
出处 《中国处方药》 2016年第9期130-131,共2页 Journal of China Prescription Drug
  • 相关文献

参考文献6

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics. CACancer J Clin, 2011, 61(2): 69-90.
  • 2Jeffery J, Lewis SJ, Ayling RM. Fecal dimeric M2-pyruvate kinase(tumor M2-PK) in the differential diagnosis offunctional and organic boweldisorders. Inflamm Bowel Dis, 2009, 15(11): 1630-1634.
  • 3Lazarev SM, Massard Zh, Reshetov AV, et al. Role of biologicaltumor markers CEA, Cyfra-2, NSE, TU M2-PK in diagnosis andtreatmentof lung cancer. Vestn Khir Im I I Grek, 2010, 169(1): 39-43.
  • 4Shastri YM, Loitsch S, Hoepffner N, et al. Comparison of anestablished simple office-based immunological FOBT with fecaltumor pyruvatekinase type M2 (M2-PK) for colorectal cancer screening:prospectivemulticenter study. Am J Gastroenterol, 2008, 103(6): 1496-1504.
  • 5Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current statusof tumor M2 pyruvate kinase( tumor M2-PK) as a biomarker ofgastrointestinalmalignancy. Ann Surg Oncol, 2007, 14(10):2714-2720.
  • 6Ewald N, Schaller M, Bayer M, et al. Fecal pyruvate kinase-M2(tumor M2-PK) measurement: a new screening concept forcolorectal cancer.Anticancer Res, 2007, 27(4A): 1949-1952.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部